Although we did not assess different CD4 subsets (Th1, Th2, Th17, Treg), we nonetheless observed superior clinical outcomes with anti-PD-1/PD-L1 therapy in patients harbouring melanomas with MHC-II expression. The gene discussed is CD4; the disease is melanoma.